Skip to main content

Table 3 Additional health care use in first week after baseline driven by (suspected) pre-eclampsia

From: Clinical value and cost analysis of the sFlt-1/PlGF ratio in addition to the spot urine protein/creatinine ratio in women with suspected pre-eclampsia: PREPARE cohort study

Patients (N)

Group A−/−

N = 124

Group B−/+

N = 47

Group C+/−

N = 15

Group D+/+

N = 13

Admission

7 (5.6)

5 (10.6)

8 (53.3)

9 (69.2)

 Mean (±SD) length of stay a

1.6 ± 0.8

4.4 ± 2.8

3.1 ± 2.6

3.0 ± 1.7

 Correct admission

1/7

4/5

4/8

9/9

Admission for immediate induction

1 (0.8)

2 (4.3)

0 (0.0)

4 (30.8)

Home monitoring

2 (1.6)

2 (4.3)

1 (6.7)

3 (23.1)

 Correct home monitoring

0/2

2/2

1/1

3/3

Additional outpatient clinic visits

30 (24.2)

20 (42.6)

11 (73.3)

2 (15.4)

 1 additional visit

21/30

14/20

7/11

1/2

 2 additional visits

8/30

5/20

4/11

1/2

 3 additional visits

1/30

1/20

0/11

0/2

  1. Data depicted as numbers (%) unless otherwise specified. Group A−/− = PCr < 30 and sFlt-1/PlGF ≤38. Group B−/+ = PCr < 30 and sFlt-1/PlGF > 38. Group C+/− = PCr ≥30 and sFlt-1/PlGF ≤38. Group D+/+ = PCr ≥30 and sFlt-1/PlGF > 38. aMean length of stay with a maximum of 7 days used in calculations